Cellyan Biotechnology Co., Ltd HKPD
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2026 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $20.3M | $16.7M | $12.6M | — |
| Operating income | — | -$2.3M | -$2.0M | -$1.8M | — |
| Net income | — | -$27.1K | $1.3M | $998.2K | — |
Balance sheet
| Fiscal year | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total assets | — | $9.4M | $8.7M | — | — |
| Total equity | — | $5.0M | $4.3M | $585.2K | -$413.6K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-086725.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $105.86B | 23.7x | 12.4% |
| COR | Cencora, Inc. | $63.15B | 41.6x | 9.3% |
| CAH | CARDINAL HEALTH INC | $57.49B | 34.2x | 14.2% |
| HLF | HERBALIFE LTD. | $1.30B | 5.6x | 0.9% |
| NUS | NU SKIN ENTERPRISES, INC. | $235.6M | 1.5x | -14.3% |
| COSM | Cosmos Health Inc. | $27.5M | — | 19.9% |
| HWH | HWH International Inc. | $14.5M | — | -30.8% |
| MEDS | DataMeds AI, Inc. | $2.8M | — | 28.7% |